Mis-Reading the Minutes: Arena Approval Follows Sell-Off Based on Advisory Committee Summary
This article was originally published in RPM Report
Arena received great news June 27: approval of the weight loss therapy Belviq with a very clean label and no special marketing restrictions. That was what Wall Street expected—except when investors read the summary of the advisory committee review of the drug published by FDA on June 22.
You may also be interested in...
Obesity Therapy Gap Or Regulatory Gap? REMS Not The Answer For Belviq Or GW Group
A common theme in FDA’s review of three different weight loss drugs has been discussion of whether a Risk Evaluation & Mitigation Strategy program can help assure appropriate use of the therapies. FDA clearly thinks the answer is “no.” But that doesn’t end the discussion of what tools can be used to help curb off-label use.
Weighty Issues: GW Obesity Drug Outcomes Project Tests a Model for Patient Input in Drug Development
A stakeholder project on obesity treatment outcomes will complete its work this summer, setting the stage for FDA to rethink efficacy endpoints for weight loss drug development. The closed-door project is happening in parallel with public advisory committee discussions on pending applications and safety standards. One impact will be to shape more formal patient-centered drug development activities in years to come.
The Inevitable Outcome: Diabetes Safety Model Expands to Weight Loss…and Beyond?
The cardiovascular outcomes standard used for diabetes drugs since 2008 is moving to weight loss. That is important in itself, but also for what it says about the lessons FDA has taken from the diabetes experience—and what it might mean about regulatory expectations for other chronic drug classes in the future.